Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
To study the safety and side effects of Ofatumumab in the treatment of chronic
graft-versus-host disease (GvHD). This study will also evaluate effectiveness of Ofatumumab
when added to standard steroid treatment for chronic graft-versus-host disease
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute